ReviewBiomarker insights2015
Biomaterial Approaches for Stem Cell-Based Myocardial Tissue Engineering.
Review in Biomarker insights, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Results from the SCIENCE and Danish ASC trials using allogeneic mesenchymal stromal cells to treat ischemic heart failure patients.Regenerative medicine · 2025Trial
- Exploring Cutting-Edge Approaches to Potentiate Mesenchymal Stem Cell and Exosome Therapy for Myocardial Infarction.Journal of cardiovascular translational research · 2024Review
- Nanoengineering of gold nanoribbon-embedded isogenic stem cell-derived cardiac organoids.RSC advances · 2023Article
- Injectable Nanocomposite Hydrogels of Gelatin-Hyaluronic Acid Reinforced with Hybrid Lysozyme Nanofibrils-Gold Nanoparticles for the Regeneration of Damaged Myocardium.ACS applied materials & interfaces · 2023Article
- Latest Advances in 3D Bioprinting of Cardiac Tissues.Advanced materials technologies · 2022Article
- Cardiac ischemia on-a-chip to investigate cellular and molecular response of myocardial tissue under hypoxia.Biomaterials · 2022Article
- Electroconductive biomaterials for cardiac tissue engineering.Acta biomaterialia · 2022Review
- Biomaterials as a Vital Frontier for Stem Cell-Based Tissue Regeneration.Frontiers in cell and developmental biology · 2022Review
- Cardiac Extracellular Matrix as a Platform for Heart Organ Bioengineering: Design and Development of Tissue-Engineered Heart.Advances in experimental medicine and biology · 2021Article
- Review Insights In Cardiac Tissue Engineering: Cells, Scaffolds, and Pharmacological Agents.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Three-dimensional scaffold-free microtissues engineered for cardiac repair.Journal of materials chemistry. B · 2020Review
- ECM Mimetic Electrospun Porous Poly (L-lactic acid) (PLLA) Scaffolds as Potential Substrates for Cardiac Tissue Engineering.Polymers · 2020Article
- Self-Healing Hydrogels: The Next Paradigm Shift in Tissue Engineering?Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Cardiac tissue-derived extracellular matrix scaffolds for myocardial repair: advantages and challenges.Regenerative biomaterials · 2019Review
- A multi-cellular 3D bioprinting approach for vascularized heart tissue engineering based on HUVECs and iPSC-derived cardiomyocytes.Scientific reports · 2018Article
- Review
- TGF-β1 combined with Sal-B promotes cardiomyocyte differentiation of rat mesenchymal stem cells.Experimental and therapeutic medicine · 2018Article
- Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration.Stem cells international · 2018Review
- Prevascularization of Decellularized Porcine Myocardial Slice for Cardiac Tissue Engineering.ACS applied materials & interfaces · 2017Article
- White paper on guidelines concerning enteric nervous system stem cell therapy for enteric neuropathies.Developmental biology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult and pluripotent stem cells represent a ready supply of cellular raw materials that can be used to generate the functionally mature cells needed to replace damaged or diseased heart tissue. However, the use of stem cells for cardiac regenerative therapies is limited by the low efficiency by which stem cells are differentiated in vitro to cardiac lineages as well as the inability to effectively deliver stem cells and their derivatives to regions of damaged myocardium. In this review, we discuss the various biomaterial-based approaches that are being implemented to direct stem cell fate both in vitro and in vivo. First, we discuss the stem cell types available for cardiac repair and the engineering of naturally and synthetically derived biomaterials to direct their in vitro differentiation to the cell types that comprise heart tissue. Next, we describe biomaterial-based approaches that are being implemented to enhance the in vivo integration and differentiation of stem cells delivered to areas of cardiac damage. Finally, we present emerging trends of using stem cell-based biomaterial approaches to deliver pro-survival factors and fully vascularized tissue to the damaged and diseased cardiac tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.